RenumathyDhanasekaranMDMD, PhD

Gastrointestinal Cancer, Hepatology & Liver Transplantation

Assistant Professor

Dr. Dhanasekaran is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
300 Pasteur Dr
# MC5500
Palo Alto, CA 94305
Phone+1 650-723-4000

Fax+1 650-498-5840

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Gastroenterology, 2012 - 2015
University of FloridaResidency, Internal Medicine, 2009 - 2012
Bangalore Medical CollegeClass of 2004

PubMed

Practical approach to diagnose and manage benign liver masses.
Reshma Reguram, Aishwarya Ghonge, Justin Tse, Renumathy Dhanasekaran
Hepatology Communications. 2024-11-01
1 citations
Spatial analysis reveals targetable macrophage-mediated mechanisms of immune evasion in hepatocellular carcinoma minimal residual disease.
Lea Lemaitre, Nia Adeniji, Akanksha Suresh, Reshma Reguram, Josephine Zhang
Nature Cancer. 2024-10-01
22 citations
Battle of the biopsies: Role of tissue and liquid biopsy in hepatocellular carcinoma.
Brandon M Lehrich, Josephine Zhang, Satdarshan P Monga, Renumathy Dhanasekaran
Journal of Hepatology. 2024-03-01

Abstracts/Posters

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling
Renumathy Dhanasekaran, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

FDA Gets Drugs Out Faster, but Some Work Only ‘Marginally’ Better and Are More Expensive • Daily MontananOctober 13th, 2024
Pharma-Funded FDA Gets Drugs Out Faster, but Some Work Only ‘Marginally’ and Most Are PriceySeptember 30th, 2022
What Does AI Mean for GI?July 6th, 2023